◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Daicel Corporation (4202)

Name: Daicel Corporation（4202）— 財務諸表の推移
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

公式財務諸表に基づく売上高、利益、キャッシュフローの推移。

Basic Materials · ウォール街（米国） · 最終更新: 2026-10-02

Daicel Corporation engages in the materials, medical/healthcare, smart, safety, and engineering plastics businesses in Japan and internationally. The company offers medical/healthcare products, including BELLOCEA S7, a spherical cellulose acetate particle; FLAVOCELL S-Equol; Urolithin A; polyglycerols; konjac ceramide; excipients for foods; chiral columns and reagents; and Actranza lab, as well as separation and analytical services.

主要指標

時価総額: JPY 359 billion
売上高（2026-03-31 期末の会計年度）: JPY 579.6B
当期純利益: JPY 10.2B
売上総利益率: 25.2%
純利益率: 1.8%

インタラクティブチャートと全財務諸表を見る → バリュエーションモデル（DCF）→

年次損益計算書

損益計算書	2026-03-31	2025-03-31	2024-03-31	2023-03-31
売上高合計	JPY 579.6B	JPY 586.5B	JPY 558.1B	JPY 538.0B
売上総利益	JPY 146.3B	JPY 164.7B	JPY 159.3B	JPY 145.8B
営業利益（EBIT）	JPY 42.1B	JPY 61.0B	JPY 62.4B	JPY 47.5B
当期純利益	JPY 10.2B	JPY 49.5B	JPY 55.8B	JPY 40.7B

出典: 企業の公開資料（SEC）。数値をご利用の前に SEC EDGAR でご確認ください。

貸借対照表、キャッシュフロー計算書、四半期データおよび全財務比率は 4202 のインタラクティブ・ビューアーでご覧いただけます。 /companies/us/4202

類似企業

本サイトの情報は教育および情報提供のみを目的としており、投資助言ではありません。目標株価や投資判断は掲載していません。

English version →全銘柄

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.